Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2020 Earnings Results

Crinetics Pharmaceuticals Misses on EPS — Stock Down 6.01%

Crinetics Pharmaceuticals reported a loss that was slightly worse than expected, leading to a 6.01% drop in stock price. The lack of revenue figures and guidance may have contributed to investor uncertainty. The company's focus on clinical programs suggests they are prioritizing long-term growth over short-term financial performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.56	N/A	-7.28%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed caution regarding the financial outlook. They emphasized their commitment to ongoing clinical development without offering specific guidance.

Management did not provide specific revenue guidance for the upcoming quarters.

The company remains focused on advancing its clinical programs despite the current challenges.

Crinetics Pharmaceuticals Misses on EPS — Stock Down 6.01%

Key numbers

Management commentary

Crinetics Pharmaceuticals, Inc.

More earnings this week

Crinetics Pharmaceuticals Misses on EPS — Stock Down 6.01%

Key numbers

Management commentary